Uber Technologies, Inc. (NYSE: UBER) and empowerDX disclosed Monday that they have joined hands to deliver FDA-emergency use authorized, at-home COVID-19 testing kits to consumers via on-demand delivery. Their partnership is beneficial for the people as their collaboration provides them the opportunity to rapidly be able to reach one of the most vulnerable at-home COVID tests on the market. It will allow them to access the test whether they are at home, in the office or traveling.

Furthermore, empowerDX at-home COVID-19 test is able to detect the virus in both symptomatic and asymptomatic sufferers. The at-home test kit is 100% protected by most insurance providers. The kit comprises step-by-step guidelines. It includes a shallow nasal swab, test tube, and a pre-paid FedEx package for easy sample returns. The empowerDX at-home test is accessible for shipment Monday through Friday from 8 a.m. to 4 p.m.

FDA has provided EUA to this in-home test kit. It has been approved by the FDA under a EUA only for the home gathering and maintenance of nasal swab specimens as assistance in the discovery of nucleic acid from SARS-CoV-2. Shares of Uber Technologies went down 0.21% at $57.81 at the time of writing on Monday.

Furthermore, it has been disclosed that consumer is required to activate their kits online. The results of the sufferers presented safely to a safe patient portal, within an average of 24-hours from sample delivery at the CLIA-certified laboratory of the firm.